245 related articles for article (PubMed ID: 16086636)
1. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.
Hanrahan EO; Hennessy BT; Valero V
Expert Opin Pharmacother; 2005 Aug; 6(9):1477-91. PubMed ID: 16086636
[TBL] [Abstract][Full Text] [Related]
2. Controversies in breast cancer: adjuvant and neoadjuvant therapy.
Montemurro F; Redana S; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2005 Jun; 6(7):1055-72. PubMed ID: 15957962
[TBL] [Abstract][Full Text] [Related]
3. When and how do I use neoadjuvant chemotherapy for breast cancer?
Rapoport BL; Demetriou GS; Moodley SD; Benn CA
Curr Treat Options Oncol; 2014 Mar; 15(1):86-98. PubMed ID: 24306808
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
5. [The development of neoadjuvant chemotherapy in breast cancer].
Taguchi T
Gan To Kagaku Ryoho; 2012 Jun; 39(6):876-81. PubMed ID: 22705682
[TBL] [Abstract][Full Text] [Related]
6. Neo-adjuvant therapy in breast cancer.
Bafaloukos D
Ann Oncol; 2005; 16 Suppl 2():ii174-81. PubMed ID: 15958453
[No Abstract] [Full Text] [Related]
7. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
8. The role of taxanes in the treatment of breast cancer.
Nabholtz JM; Gligorov J
Expert Opin Pharmacother; 2005 Jun; 6(7):1073-94. PubMed ID: 15957963
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):218-21. PubMed ID: 20654118
[No Abstract] [Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
12. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant treatment of early breast cancer: new drugs contribution].
Giacchetti S; Cuvier C; Hocini H; Bourstyn E; de Roquancourt A; Espié M
Bull Cancer; 2004 Dec; 91 Suppl 4():S232-8. PubMed ID: 15899614
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Zhang B; Hurvitz S
Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
16. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
17. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
19. [Primary systemic chemotherapy for breast cancer].
Takada M; Toi M
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1730-4. PubMed ID: 18030005
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
